Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 300 participants.
Also called NCT07279493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 300 participants
- Sponsor
- Kunming Pharmaceuticals, Inc.
- Registry
-
NCT07279493
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07279493. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-22 (actual); primary completion 2026-10-18 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of the KPCXM18 Injection in Patients With Acute Ischemic Stroke
- Acronym
- KPCXM18
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- The KPCXM18 injection
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- The KPCXM18 injection
- Lead sponsor
- Kunming Pharmaceuticals, Inc.
Record details
- Record id
cardio:ct-nct07279493- Content hash
55b2fc933e8dce94e303703c905becdadc4d30f87dc88c8869ee9bb06076b8a6